Paratesticular rhabdomyosarcoma-Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG)

被引:13
|
作者
Rogers, Timothy N. [1 ]
De Corti, Federica [2 ]
Guillen Burrieza, Gabriela [3 ]
Guerin, Florent [4 ]
van Scheltinga, Sheila Terwisscha [5 ]
Snneulders, Naima [6 ]
Craigie, Ross [7 ]
Jenney, Meriel [8 ]
Kelsey, Anna [9 ]
Zanetti, Hada [10 ]
Coppadoro, Beatrice [10 ]
De Salvo, Gian Luca [11 ]
Bisogno, Gianni [10 ]
Martelli, Helene [4 ]
机构
[1] Univ Hosp Bristol NHS Fdn Trust Bristol, Dept Paediat Surg, Bristol, Avon, England
[2] Univ Hosp Padova, Dept Womans & Childs Hlth, Pediat Surg Unit, Padua, Italy
[3] Vall dHebron Univ Hosp, Dept Paediat Surg, Barcelona, Spain
[4] Hop Univ Paris Sud, Bicetre Hosp, Dept Paediat Surg, Le Kremlin Bicetre, France
[5] Prinses Maxima Ctr Kinderoncol, Dept Paediat Surg, Utrecht, Netherlands
[6] Great Ormond St Hosp Children NHS Fdn Trust, Dept Urol, London, England
[7] Royal Manchester Childrens Hosp, Dept Paediat Surg, Manchester, Lancs, England
[8] Childrens Hosp Wales Heath Pk, Dept Pediat Oncol, Cardiff, Wales
[9] Royal Manchester Childrens Hosp, Dept Pediat Histopathol, Manchester, Lancs, England
[10] Univ Padua, Dept Womens & Childrens Hlth, Hematol Oncol Div, Padua, Italy
[11] IRCCS Ist Oncol Veneto, Clin Trials & Biostat Unit, Padua, Italy
关键词
paratesticular; pediatric; rhabdomyosarcoma;
D O I
10.1002/pbc.28479
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Paratesticular rhabdomyosarcoma (PT RMS) is rare compared to benign scrotal pathology. Inappropriate first surgery (InFS) required supplementary treatment to maintain excellent outcomes. Initial staging of regional lymph nodes is important. The aim of this study was to determine to what extent the quality of locoregional approach impacted on patient morbidity and survival. Design/methods Analysis was performed on all nonmetastatic PT RMS patients enrolled in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 protocol. Aspects assessed were adherence to surgical guidelines and impact of protocol violations, relapse analysis, and survival outcomes. Results Analysis was performed on 237 patients, with median follow up of 67.1 months. Median age was 9.0 years. InFS occurred in 75 of 237 (32%) patients. InFS required intensified chemotherapy (10) and local therapy. After InFS, 61 required primary reexcision and five delayed surgery. Of 26 recurrences, the risk of relapse was higher in patients >= 10 years (21/26) and was mainly locoregional in 16 of 26 recurrences (+/- metastatic). Sixteen of 26 died with 14 of 16 patients >= 10 years. Nodal relapse neither occurred when N1 nodes were identified at diagnosis, nor after surgical staging. Five-year overall survival (OS) at age <10 years versus >= 10 years was 98.1 and 86.7%, respectively (P = .0013). Event-free survival (EFS) at age <10 years versus >= 10 years was 95.8 and 79.6%, respectively (P = .0004). OS and EFS did not highlight a significant difference in patients undergoing appropriate versus InFS (P = .8479,P = .2780, respectively). Conclusions InFS required intensified therapy to maintain excellent OS and EFS, so better anticipation of malignancy is required. Surgical staging of the retroperitoneal lymph nodes should be performed in patients >= 10 years old.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Harrison, Douglas J.
    Qumseya, Amira
    Xue, Wei
    Arnold, Michael
    Lautz, Timothy B.
    Hiniker, Susan M.
    Thomas, Stefanie M.
    Venkatramani, Rajkumar
    Weiss, Aaron R.
    Mascarenhas, Leo
    PEDIATRIC BLOOD & CANCER, 2024, 71 (04)
  • [32] Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Vasquez, Juan C.
    Luo, Leo Y.
    Hiniker, Susan M.
    Rhee, Daniel S.
    Dasgupta, Roshni
    Chen, Sonja
    Weigel, Brenda J.
    Xue, Wei
    Venkatramani, Rajkumar
    Arndt, Carola A.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (06)
  • [33] Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Lautz, Timothy B. B.
    Xue, Wei
    Luo, Leo Y. Y.
    Fair, Douglas
    Qumseya, Amira
    Gao, Zhengya
    Dasgupta, Roshni
    Rodeberg, Dave
    Venkatramani, Rajkumar
    PEDIATRIC BLOOD & CANCER, 2023, 70 (07)
  • [34] Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Dasgupta, Roshni
    Xue, Wei
    Dixon, Andrea Hayes
    Wolden, Suzanne
    Yock, Torunn I.
    Venkatramani, Rajkumar
    Rodeberg, David A.
    PEDIATRIC BLOOD & CANCER, 2024,
  • [35] Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Joshi, D
    Anderson, JR
    Paidas, C
    Breneman, J
    Parham, DM
    Crist, W
    PEDIATRIC BLOOD & CANCER, 2004, 42 (01) : 64 - 73
  • [36] Prognostic Value of PAX-FKHR Fusion Status in Alveolar Rhabdomyosarcoma: A Report From the Cooperative Soft Tissue Sarcoma Study Group (CWS)
    Stegmaier, Sabine
    Poremba, Christopher
    Schaefer, Karl-Ludwig
    Leuschner, Ivo
    Kazanowska, Bernarda
    Bekassy, Albert N.
    Bielack, Stefan S.
    Klingebiel, Thomas
    Koscielniak, Ewa
    PEDIATRIC BLOOD & CANCER, 2011, 57 (03) : 406 - 414
  • [37] Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Rudzinski, Erin R.
    Teot, Lisa A.
    Anderson, James R.
    Moore, Julie
    Bridge, Julia A.
    Barr, Frederic G.
    Gastier-Foster, Julie M.
    Skapek, Stephen X.
    Hawkins, Douglas S.
    Parham, David M.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 140 (01) : 82 - 90
  • [38] Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
    Terwisscha van Scheltinga, Sheila
    Schoot, Reineke A.
    Routh, Jonathan C.
    Seitz, Guido
    Kao, Simon C.
    de Keizer, Bart
    Shulkin, Barry
    Ewijk, Roelof van
    Mccarville, Beth
    Casey, Dana
    Allen-Rhoades, Wendy
    Mercolini, Federico
    Merks, Hans
    Orbach, Daniel
    Kapadia, Tejas
    Walterhouse, David O.
    Davila Fajardo, Raquel
    Hiemcke-Jiwa, Laura
    Franzius, Christiane
    De Corti, Federica
    Tang, Vivian
    Metts, Jonathan
    Oberoi, Saphna
    Vokuhl, Christian
    Dasgupta, Roshni
    Birz, Suzi
    Rodeberg, David
    PEDIATRIC BLOOD & CANCER, 2025, 72 (04)
  • [39] Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe
    Lautz, Timothy B.
    Martelli, Helene
    Fuchs, Joerg
    Chargari, Cyrus
    Smeulders, Naima
    Granberg, Candace F.
    Wolden, Suzanne L.
    Sparber-Sauer, Monika
    Hawkins, Douglas S.
    Bisogno, Gianni
    Koscielniak, Ewa
    Rodeberg, David A.
    Seitz, Guido
    PEDIATRIC BLOOD & CANCER, 2023, 70 (05)
  • [40] Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram
    De Salvo, Gian Luca
    Del Bianco, Paola
    Minard-Colin, Veronique
    Chisholm, Julia
    Jenney, Meriel
    Guillen, Gabriela
    Devalck, Christine
    Van Rijn, Rick
    Shipley, Janet
    Orbach, Daniel
    Kelsey, Anna
    Rogers, Timothy
    Guerin, Florent
    Scarzello, Giovanni
    Ferrari, Andrea
    Cesen Mazic, Maja
    Merks, Johannes H. M.
    Bisogno, Gianni
    CANCER, 2024, 130 (13) : 2351 - 2360